Login to Your Account



Clinic Roundup


Wednesday, December 28, 2011
• Neuralstem Inc., of Rockville, Md., received approval from the FDA to proceed to Phase Ib testing in an ongoing trial of NSI-189 in major depressive disorder. In Phase Ia, healthy subjects received escalating doses. In the Phase Ib study, 24 depressed patients will receive escalating doses of NSI-189 over 18 daily administrations. Phase Ib will last about six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription